U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07415018) titled 'Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease' on Feb. 13.
Brief Summary: To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Study Start Date: July 22, 2026
Study Type: INTERVENTIONAL
Condition:
Leptomeningeal Disease
Intervention:
PROCEDURE: MRI Scan
Given during standard of care
DRUG: VUEWAY
Given by IV
DRUG: Gadavist
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....